Osong Medical Innovation Foundation, Korea University Research and Business Foundation

Daegu Gyeongbuk Institute of Science and Technology

Medigene, Inc.

Cha University Industry-academic Cooperation Foundation

Min-Jeong Shin

Hyeon Soo Kim

Ji Hyung Chung

Eun Hye Yoo

Eun-Kyoung Kim

Seolsong Kim

Inhyeok Jeong

The present invention relates to a composition for preventing or treating obesity or sarcopenia, containing ATPase inhibitory factor 1 (IF1) and, more specifically, to a pharmaceutical composition and a food for preventing or treating obesity or sarcopenia, containing, as an active ingredient, IF1 having an effect of suppressed appetite or effects increased muscle mass and muscle production. According to the present invention, ATPase inhibitory factor 1 (IF1) exhibits, in an obesity-induced mouse model, effects of inhibited weight gain and decreased dietary intake without side effects, and exhibits, in obesity-induced or aged mouse, effects of increased muscle mass, increased muscle protein and muscle production, and thus is very useful as an agent for preventing, alleviating or treating metabolic diseases such as obesity, an agent for suppressing appetite and an agent for preventing, alleviating or treating muscle loss-related diseases such as sarcopenia.

Pharmaceutical composition for preventing or treating obesity or sarcopenia, containing IF1 as active ingredient

The present invention pertains to an anticancer composition containing IF1 (ATPase inhibitory factor 1). The IF1 (ATPase inhibitory factor 1) according to the present invention has the effect of releasing extracellular ATP, induces cytotoxicity in various cancer cells and exhibits anticancer efficacy, and is thus very useful as an active ingredient of a powerful anticancer agent.

Anticancer pharmaceutical composition containing IF1 as active ingredient

The present invention relates to a pharmaceutical composition which is for preventing or treating obesity, and comprises a biglycan as an active ingredient. Biglycan according to the present invention suppresses appetite by decreasing the expression of Agrp and NPY, which are appetite promoting peptides, and increasing the expression of POMC, which is an appetite suppressing peptide, and thus is very useful as a medicine for treating obesity.

Appetite suppression with pharmaceutical compositions containing biglycan as an active ingredient

Growing community of inventors

Seoul, South Korea

Min-Jeong Shin